Tetra Therapeutics

Shionogi & Co. Ltd. and its US subsidiary Qpex Biopharma, Inc. are to open a shared R&D facility focused on infectious diseases and antimicrobial resistance (AMR) in San Diego in the spring of 2025

While preparing to submit the highly anticipated Phase III results for it oral COVID-19 antiviral Xocova (ensitrelvir; S-217622), Shionogi & Co. Ltd. is facing a struggle to line up other candidates

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Chinook Well Capitalized To Advances It

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . AbCellera Optimizing 500 Pot